Brendan D. Looyenga, Ph.D.
Affiliations: | 2006 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Area:
Molecular Biology, Cell Biology, Physiology BiologyGoogle:
"Brendan Looyenga"Parents
Sign in to add mentor| Gary D. Hammer | grad student | 2006 | University of Michigan | |
| (Mechanisms of tumorigenesis in the inhibin-null mouse: An analysis of dysregulated TGF-beta family signaling in steroidogenic organs.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Rosette KA, Lander SM, VanOpstall C, et al. (2021) Three-dimensional coculture provides an improved in vitro model for papillary renal cell carcinoma. American Journal of Physiology. Renal Physiology. 321: F33-F46 |
| Lodge EK, Bell JD, Roloff EM, et al. (2020) Pharmacologic inhibition of N-linked glycan trimming with kifunensine disrupts GLUT1 trafficking and glucose uptake. Biochimie |
| Rylaarsdam LE, Johnecheck GN, Looyenga BD, et al. (2019) GLUT1 is associated with sphingolipid-organized, cholesterol-independent domains in L929 mouse fibroblast cells. Biochimie |
| Lanning NJ, VanOpstall C, Goodall ML, et al. (2018) LRRK2 Deficiency Impairs trans-Golgi to Lysosome Trafficking and Endocytic Cargo Degradation in Human Renal Proximal Tubule Epithelial Cells. American Journal of Physiology. Renal Physiology |
| Looyenga B, VanOpstall C, Lee Z, et al. (2016) Determination of GLUT1 Oligomerization Parameters using Bioluminescent Förster Resonance Energy Transfer. Scientific Reports. 6: 29130 |
| Looyenga BD, Resau J, MacKeigan JP. (2013) Cytokine receptor-like factor 1 (CRLF1) protects against 6-hydroxydopamine toxicity independent of the gp130/JAK signaling pathway. Plos One. 8: e66548 |
| Looyenga BD, Mackeigan JP. (2012) Characterization of differential protein tethering at the plasma membrane in response to epidermal growth factor signaling. Journal of Proteome Research. 11: 3101-11 |
| Looyenga BD, Hutchings D, Cherni I, et al. (2012) STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. Plos One. 7: e30820 |
| Looyenga BD. (2012) Abstract 168: Cytokine signaling through the JAK2/STAT3 pathway is a viable therapeutic target in non-small cell lung cancer Cancer Research. 72: 168-168 |
| Ding Y, Huang D, Zhang Z, et al. (2011) Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets. Cancer Research. 71: 5225-34 |